• About us
• Contact

Advertisement

Product › Details

Zevtera™ (ceftobiprole medocaril)

	Next higher product group	ceftobiprole
	Status	2014-12-05 sales start
	Organisation	Basilea Pharmaceutica Ltd. (SIX: BSLN)
	Group	Basilea (Group)

Record changed: 2024-04-07

Advertisement

More documents for ceftobiprole

• [1] Basilea Pharmaceutica Ltd.. (4/4/24). "Press Release: Basilea Announces US FDA Approval of Antibiotic Zevtara (ceftobiprole medocaril) for Three Indications". Allschwil....
• [2] Basilea Pharmaceutica Ltd.. (2/27/18). "Press Release: Basilea Reports Significantly Improved Financial Results in 2017". Basel....
• [3] Basilea Pharmaceutica Ltd.. (2/23/18). "Press Release: Basilea Reports Clinical Phase 3 Study Start with Antibiotic Ceftobiprole in Skin Infections under BARDA Contract". Basel....
• [4] Basilea Pharmaceutica Ltd.. (2/21/18). "Press Release: Basilea's CEO Ronald Scott Will Retire. Chief Commercial Officer David Veitch Named as Successor – Changes in the Board of Directors". Basel....
• [5] Basilea Pharmaceutica Ltd.. (8/10/17). "Press Release: Basilea Reports Improved Financial Results in Half-year 2017 Driven by Growing Product Sales, Significant Progress on Partnering and Development Programs". Basel....
• [6] Basilea Pharmaceutica Ltd.. (4/21/17). "Press Release: Basilea Announces Agreement with FDA on Special Protocol Assessments for Antibiotic Ceftobiprole Phase 3 Clinical Studies in Bloodstream and Skin Infections". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.